Navigation Links
Rutgers researchers show how the brain can protect against cancer
Date:6/9/2008

New Brunswick, NJ--Scientists have been aware for many years that if cancer patients are not able to deal with the stress associated with being sick, the cancer will progress faster than in calmer patients. To counteract this phenomenon, physicians encourage treatments that help cancer patients handle their stress. Scientists theorized that the stress relief may have come as a result of increased beta-endorphin peptide (BEP), the "feel good" hormones in the brain that are released during exercise, a good conversation, and many other aspects of life that give humans pleasure.

Researchers at Rutgers hypothesized that BEP producing neurons do not just make us feel good, but also play roles in regulating the stress response and immune functions to control tumor growth and progression. In a paper published today in the Proceedings of the National Academy of Science, Dr. Dipak K. Sarkar and his colleagues demonstrate the physical mechanisms that support their hypothesis.

"Our findings show promise for future therapeutic treatments for bolstering the immune function," said Sarkar, professor of animal sciences and director of the Endocrinology Program at the Rutgers School of Environmental and Biological Sciences, and principal investigator of the research project.

Previous research has shown that too few, or inactive, BEP neurons are associated with various diseases. For example, low numbers of BEP neurons have been identified in the brains of patients with depression and schizophrenia. Neurons that produce too little BEP are found in many obese patients. In both these cases the patients also had higher levels of infection and more incidence of cancer.

To test their hypothesis about the role of BEP in controling tumor growth and progression, the Rutgers scientists took neural stem cells, transformed them into BEP neurons by treating them with particular chemicals, and then transplanted them into brains of live rats. The authors studied tumor growth in the rats that had been given carcinogens to induce prostate tumors. The authors noted that the BEP neurons boosted the immune system by increasing the activity of particular immune cell types and decreasing inflammation.

The neurons also protected the rats against prostate cancer 90 percent of the time. The researchers discovered that the "natural killer," or NK cells that typically attack cancer cells in the body, are activated by the inserted BEP neurons. The NK cells reduced inflammation around the cancer cells, which slowed down caner cell growth and killed many of these cells.

"We are optimistic that this research can be applied to human medicine," said Sarkar. "Instead of transplanting cells, we will investigate whether we can increase BEP using a chemical approach."


'/>"/>

Contact: Michele Hujber
hujber@aesop.rutgers.edu
732-932-7000
Rutgers University
Source:Eurekalert

Related medicine news :

1. The Healthcare Foundation of NJ awards grant to Rutgers College of Nursings Rachel Jones
2. 2 Rutgers College of Nursing Ph.D students to receive FNSNA Fellowships
3. Rutgers College of Nursings Linda Flynn to receive N.J. Governors Nursing Merit Award
4. Rutgers research partner Stemcyte, Inc., expands to New Jersey
5. The Zonta Club of Essex County honors Rutgers College of Nursings Rachel Jones
6. Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing
7. Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development
8. NJSNA honors Rutgers College of Nursings Linda Flynn for excellence in research
9. Rutgers center sparks liquid bandage, a new frontline wound treatment
10. Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award
11. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: